Adaptive Biotechnologies Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 04:30PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

Thanks, everyone, for joining us. My name is Tejas Savant, and I'm the Life Science Tools and Diagnostics Analyst at Morgan Stanley. On the stage with me are Chad Robins and Tycho Peterson, CEO and CFO of Adaptive. It's a pleasure to have you guys here.

Questions and Answers:

Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

Maybe, Chad, just to kick things off, big news this morning with the OrbiMed deal. Do you want to just spend a few minutes walking us through how the deal came about? What are the terms? And how do you see it sort of on a go-forward basis, transforming the opportunity for Adaptive?

Chad M. Robins - Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Yes, sure. But first, Tejas, thanks for having us here. I really appreciate the opportunity -- we're really excited about the OrbiMed deal. And we've been talking about for the last couple of months that we were pursuing a non
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot